Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02385266
Other study ID # STU00085782
Secondary ID R01DK100924-01
Status Terminated
Phase Phase 4
First received
Last updated
Start date September 2013
Est. completion date June 2016

Study information

Verified date April 2023
Source Northwestern University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy of D-Cycloserine versus placebo treatment in reducing pain from urological chronic pelvic pain syndrome (UCPPS).


Description:

This is a double blinded, randomized control trial (RCT) over a 21 week period that aims to evaluate the treatment efficacy of placebo and D-cycloserine(DCS) in men suffering from UCPPS. The brain functional and anatomical properties associated with treatment response will also be examined. This study will emphasize on comparing, both clinically and by brain imaging, the analgesic response to placebo in both placebo responders and non-responders in addition to a novel treatment (DCS) that targets the brain's pain mechanism for UCPPS. Subjects will be randomized to 2 arms, in a 1:1 ratio, to a DCS medication group (n=20) and a placebo medication group (n=20). Questionnaire outcomes and brain scans will occur prior to initiating treatment and at the end of the treatment period. The actual visits required are minimized, 9 visits spread out over 21 weeks, as pain, quality of life and pill ingestion timings are collected using a secure study website accessible electronically.


Recruitment information / eligibility

Status Terminated
Enrollment 24
Est. completion date June 2016
Est. primary completion date May 2016
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria: - Males greater than 18 years of age, with no racial/ethnic restrictions; - Meets diagnostic criteria for Interstitial Cystitis with Painful Bladder Syndrome (IC/PBS) and/or Chronic Prostatitis with Chronic Pelvic Pain Syndrome (CP/CPPS); - Reports symptoms of discomfort or pain in the pelvic or abdominal region for at least a 3 mo period within the last 6 mo; - Must have a Visual Analog Scale (VAS) pain score >40 mm (of 100 mm maximum) at the baseline visit (UCPPS pain moderate to severe); - Must be in generally stable health; - Must be willing to abstain from drinking alcohol during the course of the study; - Must be able to read and speak English and be willing to read and understand instructions as well as questionnaires; - Must sign an informed consent document after a complete explanation of the study documenting that they understand the purpose of the study, procedures to be undertaken, possible benefits, potential risks, and are willing to participate. Exclusion Criteria: - Urological pain associated with any systemic signs or symptoms, e.g., fever, chills; - Evidence of a facultative Gram negative or enterococcus with a value of = 100,000 CFU/ml in mid-stream urine (VB2); - Has a second chronic pain condition (e.g., chronic low back pain, temporomandibular joint syndrome, etc.) that would prevent a clear interpretation of the study results; - History of tuberculous cystitis, bladder cancer, carcinoma in situ, prostate cancer, or urethral cancer; - History of significant pelvic comorbidities, including inflammatory bowel disease (such as Crohn's disease or ulcerative colitis), has undergone pelvic radiation, systemic chemotherapy, or intravesical chemotherapy, or has been treated with intravesical Bacillus Calmette-Guerin (BCG) or unilateral orchialgia without other pelvic symptoms, has an active urethral stricture, ureteral calculi, urethral diverticulum, or has a neurological disease or disorder affecting the bladder; - Significant other medical conditions/diseases, such as significant renal disease or a history of renal insufficiency, unstable diabetes mellitus, congestive heart failure, coronary or peripheral vascular disease, chronic obstructive lung disease, or malignancy; - Neurologic disorder, including history of seizures; - Major psychiatric disorder during the past 6 months; - Moderate or severe depression, as determined by the Hospital Anxiety and Depression Scale, or any active suicidal ideation; - History of, or current, substance abuse/dependence including alcohol; - Known sensitivity to D-cycloserine; - Currently taking any of the following medications: ethionamide, dilantin, isoniazid (INH), pyridoxine (vitamin B6) - Use of therapeutic doses of antidepressant medications (i.e., tricyclic depressants, Selective Serotonin Reuptake Inhibitor (SSRIs), Serotonin-Norepinephrine Reuptake Inhibitor (SNRIs); low doses used for sleep may be allowed), as these medications can alter pain transmission; - Current use of low dose aspirin; - Indication that the subject is unlikely to be compliant due to unmanaged medical or psychological condition(s), including neurological, psychological, or speech/language problems that will interfere or prevent with his understanding of consent, his ability to comply with the protocol or ability to complete the study; - Any change in medication for urological pain in the last 30 days; - High dose opioid prophylaxis, as defined as > 50mg morphine equivalent/day; - Any medical condition that in the investigator's judgment may prevent the individual from completing the study or put the individual at undue risk; - In the judgment of the investigator, unable or unwilling to follow protocol and instructions; - Evidence of poor treatment compliance, in the judgment of the investigator; - Intra-axial implants (e.g. spinal cord stimulators or pumps); and - All exclusion criteria for Magnetic Resonance (MR) safety: any metallic implants, brain or skull abnormalities, tattoos on large body parts, and claustrophobia.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
D-Cycloserine
Pharmaceutical intervention aimed at altering central nervous system function takes place over 4.5 months with daily use of d-Cycloserine.
Placebo (for D-cycloserine)
Lactose filled capsules to mimic DCS 200mg capsules

Locations

Country Name City State
United States Northwestern University Chicago Illinois

Sponsors (3)

Lead Sponsor Collaborator
Northwestern University National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Visual Analog Scale (VAS) The visual analog scale (VAS) is a measurement tool used to assess the level of pain experienced by a patient. The scale is a 100 mm horizontal line, with one end representing "no pain" and the other end representing "worst pain imaginable." The patient is asked to mark on the line the point that best represents their level of pain.
The minimum score is 0 mm, indicating no pain, while the maximum score is 100 mm, indicating the worst pain imaginable. Higher scores on the VAS indicate a worse outcome, while lower scores indicate a better outcome.
The VAS score can be determined by measuring the distance in millimeters from the left end of the line to the point marked by the patient. The range of scores can be used to interpret the level of pain experienced by the patient, with higher scores indicating greater pain severity.
18 weeks after baseline visit
See also
  Status Clinical Trial Phase
Completed NCT04552431 - Chronic Prostatitis Collaborative Research Network Clinical Trial- Ciprofloxacin and Tamsulosin Phase 2
Not yet recruiting NCT05366517 - Repeating LiST for Refractory Non-bacterial Prostatitis/Pelvic Pain Syndrome N/A
Completed NCT00672087 - Diagnostic Challenges in IC (and Male CPPS)
Completed NCT03213938 - Acupuncture for Chronic Prostatitis/Chronic Pelvic Pain Syndrome N/A
Recruiting NCT00775515 - Laparoscopic Prostatectomy for Chronic Prostatitis Phase 2
Completed NCT01676857 - Chemokine Mechanisms in Chronic Pelvic Pain
Recruiting NCT06299683 - Pain Type and Interstitial Cystitis/Bladder Pain Syndrome Treatment N/A
Completed NCT00826514 - An Efficacy And Safety Study Of Tanezumab For The Treatment Of Pain Associated With Chronic Abacterial Prostatitis Phase 2
Completed NCT06064448 - Clinical Observation of Ningmitai Capsule in Treating Chronic Pelvic Pain Syndrome With Erectile Dysfunction Phase 4
Completed NCT04446598 - Management of Prostatodynia in Younger Patients With Non-ablative Erbium:YAG Intraurethral Laser N/A
Completed NCT00701311 - An Open-Label Study of CC-10004 for Chronic Prostatitis/Chronic Pelvic Pain Syndrome Phase 2
Completed NCT04275297 - Optimizing Psychosocial Treatment of Interstitial Cystitis/Bladder Pain Syndrome N/A
Active, not recruiting NCT05075551 - Analyzing the Brain Alterations of Acupuncture on Patients With CP/CPPS Evaluated by fMRI N/A
Recruiting NCT06385977 - Risk Factors for Chronic Prostatitis Patients in Northwest China
Completed NCT06016595 - Chronic Prostatitis/Chronic Pelvic Pain Syndrome Patients
Active, not recruiting NCT01828996 - Shocking Therapy for Chronic Pelvic Pain Syndrome N/A
Recruiting NCT03629769 - Effects of Proxelan Somministration in Patients With Chronic Prostatitis Phase 3
Recruiting NCT06345014 - The Efficacy and Safety of OM-89 in Patients With Recurrent Chronic Prostatitis/Chronic Pelvic Pain Syndrome Phase 4
Recruiting NCT06115083 - Effects of Pelvic Floor Training in Male Chronic Pelvic Pain, Correlation Between Subjective and Objective Outcomes N/A
Completed NCT03167216 - Mast Cells in Male Pelvic Pain and and Lower Urinary Tract Dysfunction Early Phase 1